Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/09/2003US20030191104 Therapy for carbohydrate metabolism disorders
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030191102 Contraception method using competitive progesterone antagonists and novel compounds useful therein
10/09/2003US20030191101 Sustained release; bioavailability; storage stability
10/09/2003US20030191100 Hypotensive agents; cardiovascular disorders; administering spironolactone
10/09/2003US20030191099 Antiestrogen compound
10/09/2003US20030191098 Synergistic mixture of thalidomide antiinflammatory agnets
10/09/2003US20030191097 Hormone replacement therapy
10/09/2003US20030191096 Administering estrogen and androgens; hormone replacement therapy; sexual disorders
10/09/2003US20030191094 Osteoporosis; dihydroxyvitamin D3; suppress gene expression of transcription factors
10/09/2003US20030191093 Pharmaceutical compositions comprising active vitamin D compounds
10/09/2003US20030191092 MMP inhibitors
10/09/2003US20030191090 Anemia therapy; hydrogenation dextrin; reacting with ferric salt; complexing
10/09/2003US20030191089 Anticancer agents
10/09/2003US20030191088 Novel therapeutic agents interfering in neutrophil migration
10/09/2003US20030191087 Skin disorders; aging and wrinkle resistance; oxyalkylation of insulin
10/09/2003US20030191086 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
10/09/2003US20030191081 Polynucleotides; gene therapy; vaccines; efficient gene expression; administering to muscles
10/09/2003US20030191080 Cardiovascular disorders; hypotensive agents
10/09/2003US20030191079 Methods for treating and preventing infectious disease
10/09/2003US20030191075 Modulation of gene expression of nucleic acids; sterol binding to oligonucleotides
10/09/2003US20030191074 Antibody therapy; immobilization
10/09/2003US20030191072 Gene therapy for proliferative vitreoretinopathy
10/09/2003US20030191070 Medical composition kit for treating lesioned abnormal tissue
10/09/2003US20030191067 Hepatitis C inhibitor tri-peptides
10/09/2003US20030191066 Side effect reduction; anticancer agents
10/09/2003US20030191064 Methods for preventing and treating loss of balance function due to oxidative stress
10/09/2003US20030191051 Combination therapy for the treatment of bacterial infections
10/09/2003US20030191050 Method and apparatus for preparing an acellular read blood cell substitute
10/09/2003US20030191048 Gene expression profile for KSHV infection and methods for treating same
10/09/2003US20030190748 In the presence of fibroblast growth factor; allows stable prolifertion and differentiation while maintaining karyotype
10/09/2003US20030190733 Desaturase genes and uses thereof
10/09/2003US20030190708 Novel hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
10/09/2003US20030190707 17 human secreted proteins
10/09/2003US20030190687 Interacts with human DR5 to produce agonistic or antagonistic effects including inhibition of cell proliferation and apoptosis; used to treat apoptosis-related disease and unregulated cell growth
10/09/2003US20030190686 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds
10/09/2003US20030190685 Bind to Tumor Necrosis Factor(TNF)-Related Apoptosis Inducing Ligand (TRAIL) receptors ; used in the prevention and treatment of cancers and other proliferative disorders
10/09/2003US20030190659 Oligomers that hybridize to Inhibition of Apoptosis (IAP) polynucleotides and methods for using them to enhance apoptosis and treat proliferative diseases
10/09/2003US20030190651 Preventing, ameliorating, correcting dysfunctions or diseases such as cancer, peripheral and central nervous system diseases, and chronic obstructive pulmonary disease
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
10/09/2003US20030190639 Diagnosis of Cryptogenetic inflammatory bowel diseases (IBDs)
10/09/2003US20030190635 RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
10/09/2003US20030190378 Extract of processed Panax genus plant, the preparation method thereof, and compositions containing the same
10/09/2003US20030190377 With enhanced pharmacological effects due to subsequent acid-or heat-treatment and bio-converting treatment such as lactic acid bacterial and intestinal bacterial fermenting; prevention or treatment of gastrointestinal diseases
10/09/2003US20030190376 Anti-Aromatase composition
10/09/2003US20030190369 Vitamin formulation for enhancing bone strength
10/09/2003US20030190367 Bone filling material formed by combining perfluoronated hydrocarbon, phospholipids, and demineralized bone matrix to putty-like consistency and molding by a piston, packaging
10/09/2003US20030190365 Mixing non-dihydrate azithromycin particles with granulating amount of granulating liquid and optionally excipients to form wet granules which comprise non-dihydrate azithromycin and the granulating liquid
10/09/2003US20030190364 Biological affinity based delivery systems
10/09/2003US20030190363 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
10/09/2003US20030190362 Pharmaceutically acceptable mixture of gelatin and hydrophobic polymer
10/09/2003US20030190361 Oxacarbazepine film-coated tablets
10/09/2003US20030190360 Chronotherapeutic pharmaceutical formulation comprising core containing active agent and delayed release compression coating comprising a natural or synthetic gum applied onto surface of core
10/09/2003US20030190359 Dosage forms for immediate release and stabilized compositions
10/09/2003US20030190357 Compositions for delivery of a cortisol antagonist
10/09/2003US20030190356 Process for preparing oral sustained-release formulation of felodipine
10/09/2003US20030190355 Modified release minerals
10/09/2003US20030190354 Venlafaxine hydrochloride in a matrix tablet dosage form, in which the the venlafaxine is mixed with a combination of hydrophillic and hydrophobic matrix forming components; antidepressant
10/09/2003US20030190353 Low water-soluble venlafaxine salts
10/09/2003US20030190352 Compositions of venlafaxine base
10/09/2003US20030190351 Venlafaxine hydrochloride and sodium carboxymethyl cellulose; antidepressant
10/09/2003US20030190350 Levothyroxine compositions having unique triiodothyronine Tmax properties
10/09/2003US20030190349 Methods of stabilizing pharmaceutical compositions
10/09/2003US20030190344 Animal feed or feed additive as performance enhancer or appetite enhancer for live stock
10/09/2003US20030190343 Palatable pharmaceutical compositions for companion animals
10/09/2003US20030190340 Gel formulations of 1-hydroxy-2(H)pyridone derivatives, which contain solvents and hydrophilic gel-forming agents
10/09/2003US20030190338 Mixtures of ascorbic acid with a monosaccharide ester of ascorbic acid and/or a metal salt of phosphorylated ascorbic acid for the treatment of dermatitis, aging and for moisturizing the skin
10/09/2003US20030190334 1S-(1 alpha ,3 alpha ,4 beta ))-2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl)-6H-puri n-6-one to treat hepatitis B virus infection
10/09/2003US20030190333 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
10/09/2003US20030190324 Immunologically significant herpes simplex virus antigens and methods for using same
10/09/2003US20030190320 Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
10/09/2003US20030190315 Reducing antibody-mediated lipid peroxidation activity in vascular systems; idiotypic antibodies; chlamydia pneumoniae vaccines
10/09/2003US20030190312 Microarray/immunoassay; for aging resistance; cytochromes; NADH oxidoreductases; lyases; cytochrome C oxidases; isomerases; GTPases
10/09/2003US20030190308 DNA vaccines (gag proteins, nef proteins) for prophylaxis and treatment of HIV infections; drug delivery
10/09/2003US20030190303 For treating allergic disorders characterized by a local immune response including inflammatory skin reactions, asthma, and arthritis
10/09/2003US20030190299 Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative
10/09/2003US20030190298 Use as skin lightening agents
10/09/2003US20030190290 And dispensing devices for improved administration of opiod analgesics such as fentanyl, alfentanil, carfentanil, remifentanil, sufentanil, buprenorphine, morphine, diamorphine
10/09/2003US20030190289 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
10/09/2003US20030190286 Propellant free buccal spray composition for transmucosal administration of pharmacologically active compound comprising 0.001-60 percent by weight immunosuppressants, mucolytics, glucocorticoids and 30-99 percent polar solvent
10/09/2003US20030190285 Having nucleotide sequence of any one of the strands of any one of the members of the High Mobility Group protein genes or LIM protein genes, including modified versions and derivatives thereof; diagnostic and therapeutic applications
10/09/2003US20030188756 Treatment of inflammatory bowel disease with vitamin d compounds
10/09/2003DE20306555U1 Orally-administered composition for prevention or treatment of osteoporosis comprises calcium, together with vitamin D3 and vitamin K1
10/09/2003CA2521305A1 Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
10/09/2003CA2519642A1 A composition and method for killing of tumours
10/09/2003CA2481795A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
10/09/2003CA2481271A1 Clarithromycin formulations having improved bioavailability
10/09/2003CA2481269A1 Taste masked compositions of erythromycin a and derivatives thereof
10/09/2003CA2481258A1 Antidiabetic agents
10/09/2003CA2481236A1 Volume efficient controlled release dosage form
10/09/2003CA2481232A1 Replikin peptides in rapid replication of glioma cells and in influenza epidemics
10/09/2003CA2480888A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003CA2480869A1 Anxiolytic agents with reduced sedative and ataxic effects
10/09/2003CA2480857A1 Improvements in pharmaceutical compositions
10/09/2003CA2480695A1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
10/09/2003CA2480686A1 Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
10/09/2003CA2480679A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
10/09/2003CA2480656A1 Bioadhesive directed somatic cell therapy
10/09/2003CA2480638A1 Substituted benzazoles and use thereof as raf kinase inhibitors
10/09/2003CA2480634A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
1 ... 5316 5317 5318 5319 5320 5321 5322 5323 5324 5325 5326 5327 5328 5329 5330 5331 5332 5333 5334 5335 5336 ... 7860